05:38 AM EDT, 09/22/2025 (MT Newswires) -- Alvotech ( ALVO ) and partner Advanz Pharma said Monday the European Medicines Agency's Committee for Medicinal Products for Human use adopted a positive opinion recommending approval for Gobivaz, the proposed biosimilar to Simponi, a biologic used to treat several chronic inflammatory diseases.

Gobivaz continues to be under EMA regulatory review, with a final decision by the European Commission pending, the company said.

Simponi is a registered trademark of Johnson & Johnson ( JNJ ) .

Alvotech ( ALVO ) shares were up 1.7% in recent premarket activity.